HRP20100580T1 - 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze - Google Patents

4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze Download PDF

Info

Publication number: HRP20100580T1
Authority: HR; Croatia
Prior art keywords: alkyl; compound; formula; image; pharmaceutically acceptable
Prior art date: 2006-04-14

Application number

HR20100580T

Other languages

English (en)

Croatian (hr)

Inventor

Cook Donald

Dakin Leslie

Del Valle David

Gero Thomas

Scott David

Zheng Xiaolan

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-14

Filing date

2010-10-25

Publication date

2010-11-30

2010-10-25 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-11-30 Publication of HRP20100580T1 publication Critical patent/HRP20100580T1/hr

Links

MOXCMUMGZFALMQ-UHFFFAOYSA-N 4-anilinoquinoline-3-carboxamide Chemical class NC(=O)C1=CN=C2C=CC=CC2=C1NC1=CC=CC=C1 MOXCMUMGZFALMQ-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract 27
150000003839 salts Chemical class 0.000 claims abstract 16
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 11
125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 48
-1 nitro, formyl Chemical group 0.000 claims 21
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 12
125000005843 halogen group Chemical group 0.000 claims 10
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
229910052739 hydrogen Inorganic materials 0.000 claims 7
239000001257 hydrogen Substances 0.000 claims 7
238000000034 method Methods 0.000 claims 7
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
229910052799 carbon Inorganic materials 0.000 claims 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
238000006243 chemical reaction Methods 0.000 claims 4
125000001153 fluoro group Chemical group F* 0.000 claims 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
125000004452 carbocyclyl group Chemical group 0.000 claims 3
150000002431 hydrogen Chemical group 0.000 claims 3
IBHNEKVLDKCEQY-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F IBHNEKVLDKCEQY-UHFFFAOYSA-N 0.000 claims 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 2
125000004093 cyano group Chemical group *C#N 0.000 claims 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
125000005842 heteroatom Chemical group 0.000 claims 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
229920006395 saturated elastomer Polymers 0.000 claims 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
KOGCUICFFHZSOM-UHFFFAOYSA-N 4-(2,3-dichloroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=CC(Cl)=C1Cl KOGCUICFFHZSOM-UHFFFAOYSA-N 0.000 claims 1
KGVQZJHSSDOJHG-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F KGVQZJHSSDOJHG-UHFFFAOYSA-N 0.000 claims 1
HJBIOYGBCCKLGS-UHFFFAOYSA-N 4-(2-fluoro-4-methylanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F HJBIOYGBCCKLGS-UHFFFAOYSA-N 0.000 claims 1
AQUQOGBEYFTABQ-UHFFFAOYSA-N 4-(2-fluoro-4-methylanilino)-7-(2-methoxyethoxy)-6-(4-propan-2-ylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(CC3)C(C)C)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F AQUQOGBEYFTABQ-UHFFFAOYSA-N 0.000 claims 1
BGYIPLCGZDFBKR-UHFFFAOYSA-N 4-(2-fluoro-5-methylanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F BGYIPLCGZDFBKR-UHFFFAOYSA-N 0.000 claims 1
VLGRXJVJJVSIPO-UHFFFAOYSA-N 4-(3-chloro-2-fluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=CC(Cl)=C1F VLGRXJVJJVSIPO-UHFFFAOYSA-N 0.000 claims 1
BBUGAAUSTUTTDJ-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-4-methylanilino)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F BBUGAAUSTUTTDJ-UHFFFAOYSA-N 0.000 claims 1
HTAUJXQLLAAXGC-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-5-methylanilino)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F HTAUJXQLLAAXGC-UHFFFAOYSA-N 0.000 claims 1
ZRFGJUOYZNQOJB-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-5-methylanilino)-6-(4-propan-2-ylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(CC3)C(C)C)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F ZRFGJUOYZNQOJB-UHFFFAOYSA-N 0.000 claims 1
229910003813 NRa Inorganic materials 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
229910021529 ammonia Inorganic materials 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
230000007062 hydrolysis Effects 0.000 claims 1
238000006460 hydrolysis reaction Methods 0.000 claims 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
125000006239 protecting group Chemical group 0.000 claims 1
239000002904 solvent Substances 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
125000003107 substituted aryl group Chemical group 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oncology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)

HR20100580T 2006-04-14 2010-10-25 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze HRP20100580T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US74485706P	2006-04-14	2006-04-14
US86509006P	2006-11-09	2006-11-09
PCT/GB2007/001338 WO2007119046A1 (en)	2006-04-14	2007-04-12	4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors

Publications (1)

Publication Number	Publication Date
HRP20100580T1 true HRP20100580T1 (hr)	2010-11-30

Family

ID=38268859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100580T HRP20100580T1 (hr)	2006-04-14	2010-10-25	4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze

Country Status (28)

Country	Link
US (1)	US20090054411A1 (de)
EP (1)	EP2010496B1 (de)
JP (1)	JP2009533405A (de)
KR (1)	KR20080112380A (de)
CN (1)	CN101466682A (de)
AR (1)	AR060508A1 (de)
AT (1)	ATE478849T1 (de)
AU (1)	AU2007238372A1 (de)
BR (1)	BRPI0710191A2 (de)
CA (1)	CA2649146A1 (de)
CY (1)	CY1111203T1 (de)
DE (1)	DE602007008710D1 (de)
DK (1)	DK2010496T3 (de)
EC (1)	ECSP088828A (de)
HK (1)	HK1126199A1 (de)
HR (1)	HRP20100580T1 (de)
IL (1)	IL194424A0 (de)
MX (1)	MX2008013212A (de)
NO (1)	NO20084202L (de)
PL (1)	PL2010496T3 (de)
PT (1)	PT2010496E (de)
RS (1)	RS51483B (de)
RU (1)	RU2008144806A (de)
SI (1)	SI2010496T1 (de)
TW (1)	TW200808732A (de)
UY (1)	UY30282A1 (de)
WO (1)	WO2007119046A1 (de)
ZA (1)	ZA200808599B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200829555A (en) *	2006-11-10	2008-07-16	Astrazeneca Ab	Chemical compounds
CL2008000191A1 (es)	2007-01-25	2008-08-22	Astrazeneca Ab	Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
UY31812A (es) *	2008-05-07	2010-01-05	Astrazeneca Ab	Derivados de cinolina como inhibidores de csf-1
TW201041869A (en) *	2009-05-14	2010-12-01	Japan Tobacco Inc	Azetidine compound and pharmaceutical use thereof
RU2582610C2 (ru)	2010-07-30	2016-04-27	Онкотерапи Сайенс, Инк.	Производные хинолина и содержащие их ингибиторы melk
WO2012061557A2 (en) *	2010-11-05	2012-05-10	Glaxosmithkline Llc	Chemical compounds
WO2012151541A1 (en) *	2011-05-05	2012-11-08	Novartis Ag	Csf-1r inhibitors for treatment of brain tumors
ES2622527T3 (es) *	2011-05-05	2017-07-06	Novartis Ag	Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
CN102584852B (zh) *	2011-12-30	2014-08-13	厦门大学	真菌代谢产物桥南霉素及其制备方法和应用
DK2753329T3 (en) *	2012-01-19	2017-10-23	Onco Therapy Science Inc	1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS
GB201211310D0 (en) *	2012-06-26	2012-08-08	Chroma Therapeutics Ltd	CSF-1R kinase inhibitors
AU2014216178B2 (en)	2013-02-15	2018-06-28	KALA BIO, Inc.	Therapeutic compounds and uses thereof
BR112015020139A2 (pt)	2013-02-20	2017-07-18	Kala Pharmaceuticals Inc	compostos terapêuticos e usos dos mesmos
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko)	2013-11-01	2016-08-19	칼라 파마슈티컬스, 인크.	치료 화합물의 결정질 형태 및 그의 용도
US10722517B2 (en)	2015-05-08	2020-07-28	Memorial Sloan Kettering Cancer Center	Compositions and methods for treatment of glioma
CN109688818A (zh)	2016-09-08	2019-04-26	卡拉制药公司	治疗化合物的晶型及其用途
AU2017324716B2 (en)	2016-09-08	2020-08-13	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (de)	2016-09-08	2020-05-20	Kala Pharmaceuticals, Inc.	Kristalline formen von therapeutischen verbindungen und verwendungen davon
CN109793737B (zh) *	2017-03-01	2021-06-29	浙江大学	苯磺酰胺结构类型雄激素受体拮抗剂及其应用
WO2022063134A1 (zh) *	2020-09-23	2022-03-31	中国科学院上海药物研究所	Csf1r激酶抑制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
BR9914164A (pt) *	1998-09-29	2001-06-26	American Cyanamid Co	Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
AU763669B2 (en) *	1998-09-29	2003-07-31	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
SE0101675D0 (sv) *	2001-05-11	2001-05-11	Astrazeneca Ab	Novel composition
EP1535910A4 (de) *	2002-05-01	2007-03-14	Kirin Brewery	Chinolinderivate und chinazolinderivate, die die autophosphorilierung des macrophage colony stimulating factor receptors inhibieren
US7618975B2 (en) *	2003-07-03	2009-11-17	Myriad Pharmaceuticals, Inc.	4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2537978C (en) *	2003-09-15	2011-08-02	Wyeth	Substituted quinolines as protein tyrosine kinase enzyme inhibitors
SE0400284D0 (sv) *	2004-02-10	2004-02-10	Astrazeneca Ab	Novel compounds
US20060264439A1 (en) *	2005-05-17	2006-11-23	Supergen, Inc.	Inhibitors of polo-like kinase-1

2007
- 2007-04-12 PL PL07732381T patent/PL2010496T3/pl unknown
- 2007-04-12 KR KR1020087027925A patent/KR20080112380A/ko not_active Application Discontinuation
- 2007-04-12 JP JP2009504814A patent/JP2009533405A/ja active Pending
- 2007-04-12 RS RSP-2010/0476A patent/RS51483B/en unknown
- 2007-04-12 AU AU2007238372A patent/AU2007238372A1/en not_active Abandoned
- 2007-04-12 RU RU2008144806/04A patent/RU2008144806A/ru not_active Application Discontinuation
- 2007-04-12 DK DK07732381.4T patent/DK2010496T3/da active
- 2007-04-12 WO PCT/GB2007/001338 patent/WO2007119046A1/en active Application Filing
- 2007-04-12 CA CA002649146A patent/CA2649146A1/en not_active Abandoned
- 2007-04-12 DE DE602007008710T patent/DE602007008710D1/de active Active
- 2007-04-12 MX MX2008013212A patent/MX2008013212A/es active IP Right Grant
- 2007-04-12 AR ARP070101556A patent/AR060508A1/es not_active Application Discontinuation
- 2007-04-12 UY UY30282A patent/UY30282A1/es unknown
- 2007-04-12 TW TW096112797A patent/TW200808732A/zh unknown
- 2007-04-12 SI SI200730379T patent/SI2010496T1/sl unknown
- 2007-04-12 EP EP07732381A patent/EP2010496B1/de active Active
- 2007-04-12 PT PT07732381T patent/PT2010496E/pt unknown
- 2007-04-12 AT AT07732381T patent/ATE478849T1/de active
- 2007-04-12 CN CNA2007800214225A patent/CN101466682A/zh active Pending
- 2007-04-12 BR BRPI0710191-0A patent/BRPI0710191A2/pt not_active IP Right Cessation
2008
- 2008-09-28 IL IL194424A patent/IL194424A0/en unknown
- 2008-10-08 ZA ZA200808599A patent/ZA200808599B/xx unknown
- 2008-10-08 NO NO20084202A patent/NO20084202L/no not_active Application Discontinuation
- 2008-10-13 US US12/250,314 patent/US20090054411A1/en not_active Abandoned
- 2008-10-17 EC EC2008008828A patent/ECSP088828A/es unknown
2009
- 2009-05-19 HK HK09104565.8A patent/HK1126199A1/xx not_active IP Right Cessation
2010
- 2010-10-21 CY CY20101100943T patent/CY1111203T1/el unknown
- 2010-10-25 HR HR20100580T patent/HRP20100580T1/hr unknown

Also Published As

Publication number	Publication date
AU2007238372A1 (en)	2007-10-25
MX2008013212A (es)	2008-10-22
HK1126199A1 (en)	2009-08-28
TW200808732A (en)	2008-02-16
ATE478849T1 (de)	2010-09-15
UY30282A1 (es)	2007-11-30
KR20080112380A (ko)	2008-12-24
ZA200808599B (en)	2009-11-25
CN101466682A (zh)	2009-06-24
IL194424A0 (en)	2009-08-03
DE602007008710D1 (en)	2010-10-07
PL2010496T3 (pl)	2011-01-31
JP2009533405A (ja)	2009-09-17
US20090054411A1 (en)	2009-02-26
RU2008144806A (ru)	2010-05-20
DK2010496T3 (da)	2010-11-08
PT2010496E (pt)	2010-10-13
EP2010496B1 (de)	2010-08-25
NO20084202L (no)	2008-10-08
CA2649146A1 (en)	2007-10-25
SI2010496T1 (sl)	2010-11-30
EP2010496A1 (de)	2009-01-07
AR060508A1 (es)	2008-06-25
ECSP088828A (es)	2008-11-27
RS51483B (en)	2011-04-30
BRPI0710191A2 (pt)	2012-06-05
WO2007119046A1 (en)	2007-10-25
CY1111203T1 (el)	2015-06-11

Publication	Publication Date	Title
HRP20100580T1 (hr)	2010-11-30	4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze
CN100384852C (zh)	2008-04-30	作为糖原磷酸化酶抑制剂的杂环酰胺衍生物
HRP20160852T1 (hr)	2016-09-23	Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
HRP20171748T1 (hr)	2017-12-29	6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba
CA2403514A1 (en)	2001-10-18	8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
RS50932B (sr)	2010-08-31	N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
ES2137113A1 (es)	1999-12-01	Nuevos derivados de triazolo-piridazinas heterociclicos.
HRP20160002T1 (hr)	2016-03-11	Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
HRP20110156T1 (hr)	2011-04-30	Monociklički heterocikli kao inhibitori kinaze
CA2225552A1 (en)	1997-02-13	Quinolones and their therapeutic use
HRP20090533T1 (en)	2009-11-30	Indolyl derivatives as liver-x-receptor modulators
CA2989722C (en)	2023-09-19	Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
NO20024154D0 (no)	2002-08-30	Pyrimidinforbindelser
MX2009011212A (es)	2009-11-02	Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
HUP0103987A2 (en)	2003-05-28	Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
MX2009011213A (es)	2009-11-02	Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
RS51574B (sr)	2011-08-31	JEDINJENJA PIROLO (2,3-d) PIRIMIDINA
YU9194A (sh)	1997-08-22	Derivati pipolo-piridina
CA2668997A1 (en)	2008-05-15	4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2006522812A5 (de)	2007-01-25
ATE218141T1 (de)	2002-06-15	Erythromycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MX2010004819A (es)	2010-07-05	Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
JP2012511588A5 (de)	2012-11-22
RU2006112845A (ru)	2007-11-10	Производные хиназолина
HRP20070117T3 (en)	2007-04-30	Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type ii diabetes